This is a working overview of cyclic heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-07 and is reviewed periodically as new material appears.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
== Structure and properties == Because of slow rotation about the N-C(O) bond, NMF exists as two rotamers that can be distinguished by NMR spectroscopy. The two principal resonance structures for one of these rotamers is shown:
American black bears have also been recorded similarly preying on elk calves in Idaho and moose calves in Alaska. Predation on adult deer is rare, but it has been recorded. They may even hunt prey up to the size of adult female moose, which are considerably larger than themselves, by ambushing them. There is at least one record of a male American black bear killing two bull elk over the course of six days by chasing them into deep snow banks, which impeded their movements. In Labrador, American black bears are exceptionally carnivorous, living largely off caribou, usually young, injured, old, sickly or dead specimens, and rodents such as voles. This is believed to be due to a paucity of edible plant life in this sub-Arctic region and a local lack of competing large carnivores (including other bear species). Like brown bears, American black bears try to use surprise to ambush their prey and target the weak, injured, sickly or dying animals in the herds. Once a deer fawn is captured, it is frequently torn apart alive while feeding. If it is able to capture a mother deer in spring, the bear frequently begins feeding on the udder of lactating females, but generally prefers meat from the viscera. Bears often drag their prey to cover, preferring to feed in seclusion. The skin of large prey is stripped back and turned inside out, with the skeleton usually left largely intact. Unlike gray wolves and coyotes, bears rarely scatter the remains of their kills. Vegetation around the carcass is usually matted down, and their droppings are frequently found nearby.
=== Aortic dissection === Fluoroquinolones can increase the rate of rare but serious tears in the aorta by 31% compared to other antibiotics. People at increased risk include those with aortic aneurysm, hypertension, certain genetic conditions such as Marfan syndrome and Ehlers–Danlos syndrome, and the elderly. For these people, fluoroquinolones should be used only when no other treatment options are available. One year after the warning announcement, prescribing behaviors were reported to have remained unchanged.
In two minor league seasons from 1989 to 1990, he had managed six home runs in 932 at bats–a ratio of 155 at bats per home run (AB/HR). With 15 home runs in his first year in Houston, that average shrunk to 36.9. He also exhibited extraordinary plate discipline for a rookie: while ranking tenth in the league in walks with 75, his OBP placed fifth at .387. Of the power surge, commented Bagwell to hitting coach Rudy Jaramillo, "That's awesome", to which he reacted, "Awesome? We can get more out of you than that." By altering an approach to contact the pitch with topspin as he did when he arriving to Houston, Jaramillo taught Bagwell to hit with backspin, resulting in a soaring trajectory rather than nose diving. He also habituated Bagwell to manipulate the count, waiting for a pitch to drive instead of indiscriminately swinging at any pitch that appeared to be a strike. Accounted Bagwell of the newfound advantage, "I didn't hit many home runs in the minor leagues, but when I hit one, when I got backspin on it, it went a long way." Although firmly established as the Astros' first baseman from Opening Day in 1991, Bagwell remarked years later that transitioning from third base was not automatic. First basemen approach fielding plays from their right side, which is opposite to playing third base. He recounted one conversation that occurred during an Astros pitching change in a game against St. Louis. Shortstop Ozzie Smith was on first and asked Bagwell, "How's it going?" Bagwell responded, "I'm really struggling with my backhand." Smith replied, "Well, here's what you do.
== Awards == 1988 Du Vigneaud Award for Young Investigators in Peptide Research 1989 Protein Society Young Investigator Award 1992 Eli Lilly Award in Biological Chemistry 1993 DuPont Merck Summit Award 1995 Fellow, American Association for the Advancement of Science 1998 Fellow, AAAS 1999 Member, National Academy of Sciences (U.S.A.) 2003 The American Peptide Society Merrifield Award 2008 The American Chemical Society Ralph F. Hirschmann Award in Peptide Chemistry 2009 The American Peptide Society Makineni Award 2015 The Stein & Moore Award of the Protein Society 2016 Weizmann Institute Max Perutz Memorial Lecture 2018 The American Chemical Society Cope Scholar Award 2018 The American Chemical Society Murray Goodman Memorial Prize 2020 The Franklin Institute & City Council of Philadelphia John C. Scott Award 2025 ACS Ronald Breslow Award for Achievement in Biomimetic Chemistry
Sources: en.wikipedia.org
=== Other anabolic agents === Clenbuterol – a beta-agonist; anabolic ability dubious Selective androgen receptor modulators (SARMs) Tibolone – a synthetic steroid Zeranol – a nonsteroidal estrogen Zilpaterol – a beta2-agnoist; anabolic ability dubious
=== Union of Economic Interests === During the First Portuguese Republic, associations of employers took two different approaches to promote their interests. Before 1924, they attempted to exert political power indirectly, by influencing the government and its economic policies. After 1924, they form the Union of Economic Interests (UEI) as an attempt to exert political power directly. The UEI was led by the Commercial Association of Lisbon and also included members of other employer associations, including the União Agrária (Agrarian Union), the Associação Industrial Portuguesa (Portuguese Industrial Association) and the Associação Comercial de Lojistas (Commercial Association of Shopkeepers). Part of the UEI's political strategy included the acquisition of newspapers, including O Primeiro de Janeiro, the Diário de Notícias and O Século.
Agroecology Alligator farm Certification for Aquaculture Professionals Fisheries science Fishery Industrial aquaculture List of commercially important fish species Maggots used as food for fish Oyster farming Recirculating aquaculture system Resource decoupling
Small humanin-like peptides (SHLPs) are a group of peptides encoded in the 16S ribosomal RNA region of mitochondrial genome. Six peptides of this group (SHLP1–6) have been identified so far, between 20-38 amino acids in length. They are derived from the mitochondria and act as important retrograde signaling molecules in the cell. Their names were given because the SHLPs share some similar biological effects with the mitochondrial peptide Humanin. Every individual SHLP showed unique expression pattern in mouse tissues. Specifically, SHLP1 was detected in the heart, kidney, and spleen; SHLP2 was detected in the liver, kidney, and muscle; SHLP3 was detected in the brain and spleen; SHLP4 was detected in the liver and prostate; and SHLP6 was detected in the liver and kidney. Experiments using cultured mammalian cells have shown that SHLPs are bioactive peptides. Incubation of each synthetic SHLP with cells affected cell viability, proliferation and apoptosis differentially, which suggests that every SHLP may play a different role in the biological system.
Methylenetetrahydrofolate reductase (MTHFR) is the rate-limiting enzyme in the methyl cycle, and it is encoded by the MTHFR gene. Methylenetetrahydrofolate reductase catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a cosubstrate for homocysteine remethylation to methionine. Natural variation in this gene is common in otherwise healthy people. Although some variants have been reported to influence susceptibility to occlusive vascular disease, neural tube defects, Alzheimer's disease and other forms of dementia, colon cancer, and acute leukemia, findings from small early studies have not been reproduced. Some mutations in this gene are associated with methylenetetrahydrofolate reductase deficiency. Complex I deficiency with recessive spastic paraparesis has also been linked to MTHFR variants. In addition, the aberrant promoter hypermethylation of this gene is associated with male infertility and recurrent spontaneous abortion.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.